Nature gave us two kidneys for redundancy. We can engineer the same redundancy for the heart. Not a replacement. Not a constant assist. A standby that activates in 1.8 seconds when the primary fails.
Cardiac medicine has made extraordinary advances. Pacemakers regulate rhythm. LVADs assist one ventricle. Total artificial hearts replace the original entirely. Each is a genuine breakthrough. But each also has a fundamental limitation that no existing device has solved.
| Device | What it does | What it cannot do |
|---|---|---|
| Pacemaker | Regulates electrical rhythm | Does not pump blood |
| LVAD | Assists left ventricle continuously | External power, not a failover system |
| Total artificial heart | Replaces the biological heart | Loses the original heart forever |
| Defibrillator (ICD) | Shocks abnormal rhythm | Does not maintain circulation |
| The Standby Heart | Dormant until H1 fails — then activates instantly | Keeps original heart. No constant intervention. |
"Nobody has built a fully implanted standby cardiac pump that activates only on failure. That is the gap. That is the idea."
A car engine does not stop when one spark plug fails — the others compensate instantly. The same principle applied to the heart. Not a replacement running constantly. Not a device that interferes with the primary heart's function. A dormant standby pump that does nothing until the primary heart fails — then activates in under 2 seconds.
The French Carmat artificial heart proved that total cardiac replacement works. That is a magnificent achievement. But this is different. The Standby Heart keeps the original biological heart intact and functioning — adding redundancy alongside it, not instead of it. Two hearts coexisting. One runs. One waits.
Two pumps in one chest cavity raises real engineering challenges. Space is tight. Blood flow from two sources must not conflict. The VSG must switch in under one second without creating turbulence or clotting. The coexistence of H1 and H2 — one biological, one mechanical — requires haemodynamic coordination that has not been attempted at this scale.
But the components exist. LVAD technology has proven that miniaturised cardiac pumps can function reliably for years inside the human body. Wireless power transfer already operates in some implanted devices. Bio-compatible titanium and polymer housings are established materials. The engineering challenge is integration and coordination — not invention of new components. That is a harder problem than it sounds. It is also a solvable one.
With AI, the timeline collapses. Computational fluid dynamics models blood flow through the VSG design in days. Material selection algorithms find the optimal polymer combinations for the H2 housing before a single prototype is machined. AI cardiac monitoring achieves millisecond failure detection with training data from millions of cardiac events. The device can be designed, simulated, and optimised computationally before any physical prototype exists.
This is not a 20-year PhD. With the right team, the right tools, and the devotion to the cause — it is a 5-year sprint. The devotion is the rarest ingredient. The technology is not.
One brilliant biomedical engineer. One cardiac surgeon as clinical advisor — ideally someone who has watched patients die in the 4-minute window between cardiac arrest and intervention. One AI and simulation specialist. $2–5M in focused funding. Five years of complete devotion to one problem.
The French team behind Carmat has solved the hardest materials and biocompatibility problems for total artificial hearts. Their work is the closest existing foundation. Stanford Biodesign, Johns Hopkins Biomedical Engineering, IIT Bombay, and AIIMS Cardiac Surgery are natural starting points for collaboration. The Carmat team itself would be worth approaching — they built the hardest part of the hardware stack already.
Someone who wakes up every morning thinking about two hearts. That person will build this. This idea is waiting for them.
This concept is released freely into the world. No patent. No equity stake required. No permission needed. If a young biomedical engineer reads this in 2026 and builds it by 2031 — that is the whole point. The only ask: save lives.